Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Creating Clinical Site Close-Out Checklist – V 2.0

Posted on By

BA-BE Studies: SOP for Creating Clinical Site Close-Out Checklist – V 2.0

Standard Operating Procedure for Creating Clinical Site Close-Out Checklist in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/128/2025
Supersedes SOP/BA-BE/128/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for preparing and executing a standardized Clinical Site Close-Out Checklist for bioavailability/bioequivalence (BA/BE) studies, ensuring all site activities are properly concluded and documented.

2. Scope

This SOP applies to study monitors, clinical research associates (CRAs), and project managers involved in the site close-out process for BA/BE clinical trials.

3. Responsibilities

  • CRA/Monitor: Prepares and executes the site close-out checklist and coordinates documentation retrieval.
  • Principal Investigator: Ensures completeness of study documentation and archiving.
  • QA Personnel: Reviews checklist completion and ensures regulatory compliance.
  • Project Manager: Ensures sponsor requirements for site closure are met.

See also  BA-BE Studies: SOP for Blinding and Unblinding Protocols in BA/BE Studies - V 2.0

4. Accountability

The Clinical Trial Manager is accountable for ensuring all elements of the close-out checklist are addressed and appropriately documented prior to formal site closure.

5. Procedure

5.1 Initiating Close-Out

  1. Initiate close-out checklist once the last subject’s last visit (LSLV) and data collection are complete.
  2. Notify site via formal communication using Annexure-1: Site Close-Out Notification Template.

5.2 Close-Out Checklist Preparation

  1. Download and customize Annexure-2: Site Close-Out Checklist.
  2. Checklist must include, at minimum:
    • Final subject log and accountability forms
    • Resolution of data queries and protocol deviations
    • Archiving of source documents and CRFs
    • Return or destruction of IP and unused materials
    • Verification of signed informed consent documents
    • Confirmation of SAE reports submission and closure

5.3 On-Site Close-Out Visit

  1. Conduct the visit in the presence of the PI and study coordinator.
  2. Verify:
    • All essential documents are in the Investigator Site File (ISF)
    • All subject-related documents are completed and signed
    • Storage conditions of archived documents are compliant
  3. Document observations and pending actions in Annexure-3: Site Close-Out Visit Report.
See also  BA-BE Studies: SOP for Handling Serious Adverse Events (SAEs) - V 2.0

5.4 Final Sign-Off and Archival

  1. Review completed checklist and ensure no open action items remain.
  2. PI and CRA must sign off Annexure-4: Site Close-Out Certification Form.
  3. Archive all original documents at the site and send copies to sponsor/CRO.

5.5 Communication to Sponsor and Ethics Committee

  1. Send formal notification of site closure to the sponsor and Institutional Ethics Committee (IEC) using Annexure-5.
  2. Include summary of:
    • Subjects enrolled and completed
    • Adverse events reported
    • Final ISF content verification

6. Abbreviations

  • CRA: Clinical Research Associate
  • PI: Principal Investigator
  • ISF: Investigator Site File
  • CRF: Case Report Form
  • IP: Investigational Product
  • IEC: Institutional Ethics Committee

7. Documents

  1. Site Close-Out Notification Template – Annexure-1
  2. Site Close-Out Checklist – Annexure-2
  3. Site Close-Out Visit Report – Annexure-3
  4. Site Close-Out Certification Form – Annexure-4
  5. Site Closure Communication to IEC/Sponsor – Annexure-5

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules, India
  • CDSCO Inspection Checklist

9. SOP Version

Version: 2.0

See also  BA-BE Studies: SOP for Pre-Submission Meeting with Regulatory Authorities - V 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Site Close-Out Notification Template

Date Site Name Study Code PI Notification By
15/04/2025 ABC Clinical Unit BE-128 Dr. Meena Joshi Rajesh Kumar

Annexure-2: Site Close-Out Checklist

Task Status Remarks
All CRFs completed and signed Yes Verified by CRA
IP returned/destructed Yes Destruction Certificate filed

Annexure-3: Site Close-Out Visit Report

Date CRA PI Summary of Activities
16/04/2025 Sunita Reddy Dr. Meena Joshi Documents verified, ISF archived

Annexure-4: Site Close-Out Certification Form

Site PI Name CRA Name Certification Date
ABC Clinical Unit Dr. Meena Joshi Sunita Reddy 17/04/2025

Annexure-5: Site Closure Communication to IEC/Sponsor

Date Recipient Summary Contents Submitted By
18/04/2025 IEC Chairperson Final subject data, AE summary, ISF status Rajesh Kumar

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial Release Regulatory Compliance QA Head
17/04/2025 2.0 Included templates for formal IEC closure communication Audit Observation QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Creams: SOP for Ensuring Homogeneity in Cream Batches – V 2.0
Next Post: Biosimilars: SOP for Establishing Clone Performance Metrics – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version